Contribution of HLA-DRB1*04 alleles and anti-cyclic citrullinated antibodies to development of resistance to disease-modifying antirheumatic drugs in early rheumatoid arthritis

Clinical Rheumatology

Volumn 29, Issue 12, 2010, Pages 1357-1366

  Mori, Shunsuke ^c   Hirose, Jun ^a   Yonemura, Kensuke ^b  

^a KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^b Kumamoto Saishunsou National Hospital   (Japan)

^c NONE

Author keywords

Anti cyclic citrullinated peptide antibodies; Disease modifying antirheumatic drug; HLA DRB1 04; Methotrexate; Rheumatoid arthritis; Shared epitope

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HLA DR ANTIGEN; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE; TACROLIMUS; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG SENSITIVITY; DRUG SUBSTITUTION; FEMALE; GENE FREQUENCY; HUMAN; JAPANESE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHARMACOGENETICS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS;

AGED; ALLELES; ANTIBODIES; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG RESISTANCE; EPITOPES; FEMALE; GENE FREQUENCY; HLA-DR ANTIGENS; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PEPTIDES, CYCLIC; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649324263     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-010-1454-y     Document Type: Article

References (45)

1. W Ollier W Thomson 1992 Population genetics of rheumatoid arthritis Rheum Dis Clin North Am 18 741 759 1:STN:280:DyaK3s%2FoslyitA%3D%3D 1280845
2. PK Gregersen J Silver RJ Winchester 1987 The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis Arthritis Rheum 30 1205 1213 1:CAS:528:DyaL1cXhtVOisbY%3D 10.1002/art.1780301102 2446635 (Pubitemid 18005792)
3. R Winchester E Dwyer S Rose 1992 The genetic basis of rheumatoid arthritis. The shared epitope hypothesis Rheum Dis Clin North Am 18 761 783 1:STN:280:DyaK3s%2FoslyitQ%3D%3D 1280846
4. JD Gorman LA Criswell 2002 The shared epitope and severity of rheumatoid arthritis Rheum Dis Clin North Am 28 59 78 10.1016/S0889-857X(03)00069-3 11840698 (Pubitemid 34111677)
5. G Moxley HJ Cohen 2002 Genetic studies, clinical heterogeneity, and disease outcome studies in rheumatoid arthritis Rheum Dis Clin North Am 28 39 58 10.1016/S0889-857X(03)00068-1 11840697 (Pubitemid 34111676)
6. T Sokka T Pincus 2002 Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients J Rheumatol 29 2521 2524 1:CAS:528:DC%2BD3sXntFyj 12465145
7. ME Weinblatt 1995 Efficacy of methotrexate in rheumatoid arthritis Br J Rheumatol 34 Suppl 2 43 48 8535649
8. B Combe R Landewe C Lukas, et al. 2007 EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT) Ann Rheum Dis 66 34 45 1:STN:280:DC%2BD28jjvFCmsw%3D%3D 10.1136/ard.2005.044354 16396980 (Pubitemid 46044858)
9. FC Breedveld MH Weisman AF Kavanaugh, et al. 2006 The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment Arthritis Rheum 54 26 37 1:CAS:528:DC%2BD28XhsVens74%3D 10.1002/art.21519 16385520 (Pubitemid 43122183)
10. EW St Clair DM van der Heijde JS Smolen, et al. 2004 Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial Arthritis Rheum 50 3432 3443 1:CAS:528: DC%2BD2cXhtVOqtrvJ 10.1002/art.20568 15529377 (Pubitemid 39488667)
11. J Kekow RJ Moots P Emery, et al. 2010 Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial Ann Rheum Dis 69 222 225 1:CAS:528:DC%2BC3cXhtFOlsLw%3D 10.1136/ard.2008.102509 19293160
12. YP Goekoop-Ruiterman JK de Vries-Bouwstra CF Allaart, et al. 2005 Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial Arthritis Rheum 52 3381 3390 1:CAS:528:DC%2BD2MXht1KrtbfL 10.1002/art.21405 16258899 (Pubitemid 41612204)
13. MA Quinn PG Conaghan PJ O'Connor, et al. 2005 Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial Arthritis Rheum 52 27 35 1:CAS:528:DC%2BD2MXht1KisLY%3D 10.1002/art.20712 15641102 (Pubitemid 40129229)
14. GA Schellekens H Visser BA de Jong, et al. 2000 The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide Arthritis Rheum 43 155 163 1:CAS:528:DC%2BD3cXns1ygtg%3D%3D 10.1002/1529- 0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3 10643712 (Pubitemid 30368225)
15. S Mori H Naito S Ohtani T Yamanaka M Sugimoto 2009 Diagnostic utility of anti-cyclic citrullinated peptide antibodies for rheumatoid arthritis in patients with active lung tuberculosis Clin Rheumatol 28 277 283 10.1007/s10067-008-1035-5 19002544
16. EJ Kroot BA de Jong MA van Leeuwen, et al. 2000 The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis Arthritis Rheum 43 1831 1835 1:CAS:528:DC%2BD3cXmtFKju7w%3D 10.1002/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6 10943873 (Pubitemid 30640938)
17. O Meyer C Labarre M Dougados, et al. 2003 Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage Ann Rheum Dis 62 120 126 1:CAS:528: DC%2BD3sXhtlSiu7Y%3D 10.1136/ard.62.2.120 12525380 (Pubitemid 36135386)
18. K Forslind M Ahlmen K Eberhardt I Hafstrom B Svensson 2004 Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP) Ann Rheum Dis 63 1090 1095 1:CAS:528:DC%2BD2cXnvFWkt7k%3D 10.1136/ard.2003.014233 15308518 (Pubitemid 39120360)
19. AH van der Helm-van Mil KN Verpoort FC Breedveld RE Toes TW Huizinga 2005 Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis Arthritis Res Ther 7 R949 R958 10.1186/ar1767 16207336
20. FA van Gaalen SP Linn-Rasker WJ van Venrooij, et al. 2004 Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study Arthritis Rheum 50 709 715 10.1002/art.20044 15022309 (Pubitemid 38326168)
21. S Rantapaa-Dahlqvist BA de Jong E Berglin, et al. 2003 Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis Arthritis Rheum 48 2741 2749 10.1002/art.11223 14558078 (Pubitemid 37280601)
22. E Berglin T Johansson U Sundin, et al. 2006 Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset Ann Rheum Dis 65 453 458 1:STN:280:DC%2BD287ktFKjsA%3D%3D 10.1136/ard.2005.041376 16176994
23. FC Arnett SM Edworthy DA Bloch, et al. 1988 The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arthritis Rheum 31 315 324 1:STN:280:DyaL1c7pt1Ohsg%3D%3D 10.1002/art. 1780310302 3358796
24. K Migita T Nakamura Y Maeda, et al. 2006 HLA-DRB1*04 alleles in Japanese rheumatoid arthritis patients with AA amyloidosis J Rheumatol 33 2120 2123 17086601
25. SP Linn-Rasker AH van der Helm-van Mil FA van Gaalen, et al. 2006 Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles Ann Rheum Dis 65 366 371 1:CAS:528:DC%2BD28XisFCjtb4%3D 10.1136/ard.2005.041079 16014670 (Pubitemid 43268227)
26. A MacGregor W Ollier W Thomson D Jawaheer A Silman 1995 HLA-DRB1*0401/0404 genotype and rheumatoid arthritis: increased association in men, young age at onset, and disease severity J Rheumatol 22 1032 1036 1:STN:280:DyaK2MvgsVGgtw%3D%3D 7674226
27. JJ Goronzy EL Matteson JW Fulbright, et al. 2004 Prognostic markers of radiographic progression in early rheumatoid arthritis Arthritis Rheum 50 43 54 10.1002/art.11445 14730598 (Pubitemid 38084286)
28. JD Gorman RF Lum JJ Chen ME Suarez-Almazor G Thomson LA Criswell 2004 Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3, 240 rheumatoid arthritis patients Arthritis Rheum 50 400 412 10.1002/art.20006 14872482 (Pubitemid 38198824)
29. D van Zeben JM Hazes AH Zwinderman, et al. 1991 Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a follow up study Arthritis Rheum 34 822 830 10.1002/art.1780340707 2059230
30. U Wagner S Kaltenhauser H Sauer, et al. 1997 HLA markers and prediction of clinical course and outcome in rheumatoid arthritis Arthritis Rheum 40 341 351 1:STN:280:DyaK2s7psVGjug%3D%3D 10.1002/art.1780400219 9041946 (Pubitemid 27114098)
31. CM Weyand TG McCarthy JJ Goronzy 1995 Correlation between disease phenotype and genetic heterogeneity in rheumatoid arthritis J Clin Invest 95 2120 2126 1:CAS:528:DyaK2MXltlWrt7k%3D 10.1172/JCI117900 7738179
32. MA Gonzalez-Gay AH Hajeer C Garcia-Porrua, et al. 2002 Patients chosen for treatment with cyclosporine because of severe rheumatoid arthritis are more likely to carry HLA-DRB1 shared epitope alleles, and have earlier disease onset J Rheumatol 29 271 275 1:CAS:528:DC%2BD38XhsF2iu74%3D 11842822
33. LR Lard M Boers A Verhoeven, et al. 2002 Early and aggressive treatment of rheumatoid arthritis patients affects the association of HLA class II antigens with progression of joint damage Arthritis Rheum 46 899 905 1:CAS:528:DC%2BD38Xjs12lt7w%3D 10.1002/art.10151 11953965 (Pubitemid 34303800)
34. H Marotte B Pallot-Prades L Grange, et al. 2006 The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population Ann Rheum Dis 65 342 347 1:CAS:528:DC%2BD28XisFCjtL0%3D 10.1136/ard.2005.037150 16096333 (Pubitemid 43268223)
35. E Berglin L Padyukov U Sundin, et al. 2004 A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis Arthritis Res Ther 6 R303 R308 1:CAS:528:DC%2BD2cXkvVOhur4%3D 10.1186/ar1187 15225365
36. FA van Gaalen J van Aken TW Huizinga, et al. 2004 Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis Arthritis Rheum 50 2113 2121 10.1002/art.20316 15248208 (Pubitemid 38924388)
37. S Kaltenhauser M Pierer S Arnold, et al. 2007 Antibodies against cyclic citrullinated peptide are associated with the DRB1 shared epitope and predict joint erosion in rheumatoid arthritis Rheumatology (Oxford) 46 100 104 1:STN:280:DC%2BD28jis12hsw%3D%3D 10.1093/rheumatology/kel052 (Pubitemid 44932795)
38. R Sanmarti A Gomez-Centeno G Ercilla, et al. 2007 Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids Clin Rheumatol 26 1111 1118 1:STN:280:DC%2BD2szgvV2isw%3D%3D 10.1007/s10067-006-0462-4 17109060 (Pubitemid 46863954)
39. TW Huizinga CI Amos AH van der Helm-van Mil, et al. 2005 Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins Arthritis Rheum 52 3433 3438 1:CAS:528:DC%2BD2MXht1Krur7O 10.1002/art.21385 16255021 (Pubitemid 41612209)
40. AH van der Helm-van Mil KN Verpoort FC Breedveld TW Huizinga RE Toes RR de Vries 2006 The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis Arthritis Rheum 54 1117 1121 10.1002/art.21739 16572446 (Pubitemid 43672924)
41. WH Bos J Ursum N de Vries, et al. 2008 The role of the shared epitope in arthralgia with anti-cyclic citrullinated peptide antibodies (anti-CCP), and its effect on anti-CCP levels Ann Rheum Dis 67 1347 1350 1:STN:280: DC%2BD1crhtlaksg%3D%3D 10.1136/ard.2008.089953 18388157
42. D Mewar A Coote DJ Moore, et al. 2006 Independent associations of anti-cyclic citrullinated peptide antibodies and rheumatoid factor with radiographic severity of rheumatoid arthritis Arthritis Res Ther 8 R128 10.1186/ar2017 16859535
43. Y Toda S Takemura H Komuro, et al. 1997 Relationship between duration of rheumatoid arthritis before knee joint surgery and HLA-DRB1 alleles: a retrospective study J Rheumatol 24 2304 2307 1:STN:280:DyaK1c%2Fns1Witg%3D%3D 9415632
44. S Wakitani N Murata Y Toda, et al. 1997 The relationship between HLA-DRB1 alleles and disease subsets of rheumatoid arthritis in Japanese Br J Rheumatol 36 630 636 1:STN:280:DyaK2sznvFyksA%3D%3D 10.1093/rheumatology/36.6.630 9236671
45. H Nakamura S Yoshino N Ishiuchi J Fujimori T Kanai Y Nishimura 1997 Outcome of radical multiple synovectomy as a novel surgical treatment for refractory rheumatoid arthritis: implication of HLA-DRB1*0405 in post-operative results Clin Exp Rheumatol 15 53 57 1:STN:280: DyaK2s3kslKntA%3D%3D 9093773